- Will CAR-NK Cancer Therapy Surpass High-Cost CAR-T Immunotherapy?
- What is the role of Platelet Dynamics in Cancer Progression?
- Biomarkers can detect rapid aging of organs and disease risks
- Avoiding “Off-Target” Effects: Researchers Enhance the Safety of Future mRNA Therapies
- Japan: Sales Halted for ‘Cannabis Gummies’ as Health Issues Mount
- Evaluation of the carcinogenicity of organic fluorine compounds raised by WHO subsidiary
WHO approved China SINOPHARM COVID-19 vaccine for emergency use
WHO approved China SINOPHARM COVID-19 vaccine for emergency use. On May 07, 2021, The World Health Organization approved the emergency use of the coronavirus vaccine produced by China’s SINOPHARM, which makes it possible that the SINOPHARM vaccine may be included in the UN-supported COVAX project in the next few weeks or months and passed UNICEF and Distributed by the WHO Regional Office for the Americas.
There are two SINOPHARM vaccines in China. They were developed by SINOPHARM’s Institute of Biological Products in Beijing and Wuhan. The vaccine developed by SINOPHARM in Beijing came out first. The WHO is reviewing whether to approve this one.
SINOPHARM Beijing developed the first vaccine approved for emergency use in China, with the largest domestic supply and inoculation volume, and it is also the most widely used Chinese vaccine approved worldwide. The vaccine data developed in Wuhan showed slightly lower efficacy. There are very few publicly released data on the SINOPHARM vaccine. In December 2020, SINOPHARM issued a statement stating that the clinical phase III interim data showed that the vaccine is effective in preventing new coronavirus symptoms at 79%. Test results from Brazil, Turkey and Indonesia show that its immune efficacy ranges from 50.7% to 83.5%.
WHO Director-General Tan Desai said: “This afternoon, WHO approved the emergency use list of SINOPHARM Beijing New coronavirus Pneumonia Vaccine, making it the sixth vaccine that has obtained WHO’s safety, effectiveness and quality certification. “This expands the list of vaccines that COVAX can buy, and gives countries the confidence to speed up their regulatory approvals and the import and use of vaccines.” WHO’s main criteria for evaluating vaccines include an efficiency of at least 50% and production and manufacturing standards.
Another group that provides vaccine advice to UN agencies said that the SINOPHARM vaccine is “very confident” that it can protect people aged 18-59. The organization stated that they have “lack of confidence” in the effectiveness of the vaccine in people 60 years of age and older because they have “very lack of confidence” in the existing data on serious side effects in this age group.
(source:internet, reference only)